OncoMatch/Clinical Trials/NCT06288373
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
Is NCT06288373 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including Camrelizumab and Cisplatin for cervical cancer.
Treatment: Camrelizumab · Cisplatin · Nab paclitaxel · Cisplatin — It is a prospective, open-label, randomized, controlled phase II/III clinical trial in which patients with PD-L1-positive FIGO stage IB3, IIA2 and IIB（tumors \>4 cm in diameter）will be enrolled and randomly divided into the neoadjuvant chemoimmunotherapy plus surgery group and the CCRT group.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Biomarker criteria
Required: PD-L1 (CD274) positive expression, Combined Positive Score (CPS) ≥1 (CPS ≥1)
Positive PD-L1 expression, Combined Positive Score (CPS) ≥1
Disease stage
Required: Stage IIB
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immune checkpoint inhibitor
Prior treatment with immune checkpoint inhibitors, including but not limited to other anti-PD-1 and anti-PD-L1 antibodies
Lab requirements
Blood counts
WBC ≥ 3.5×10^9/L, NEU ≥ 1.5×10^9/L, PLT ≥ 100×10^9/L
Kidney function
serum creatinine (BUN) ≤ 1.5x ULN or creatinine clearance ≥ 50 mL/min
Liver function
total bilirubin ≤ 1.5x ULN; ALT and AST ≤ 1.5x ULN
Laboratory tests: WBC (white blood cell count) ≥ 3.5×109/L, NEU (neutrophil count) ≥ 1.5×109/L, PLT (platelet count) ≥ 100×109/L, total bilirubin ≤ 1.5 times the upper limit of normal, ALT (alanine aminotransferase) and AST (aspartate aminotransferase) ≤ 1.5 times the upper limit of normal, serum creatinine (BUN) ≤ 1.5 times the upper limit of normal or creatinine clearance ≥ 50 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify